KLAC vs SYRE · P/E 55, rev $13.58B vs $7.60B cap
KLA Corporation (KLAC) versus Spyre Therapeutics Inc. (SYRE) — a side-by-side from cached financials, not a winner call.
KLA Corporation (KLAC) is a semiconductor equipment & materials company listed on US. It is led by Richard P. Wallace.
Spyre Therapeutics Inc. (SYRE) is a biotechnology company listed on NASDAQ.
Latest reported KLAC revenue for 2026-06-30 was $13.58B. Net income was $4.83B. Revenue was up 11.7% from 2025-06-30 to 2026-06-30. KLAC currently screens at market cap $252.01B and trailing P/E 54.7.
Latest reported SYRE revenue for 2025-12-31 was $0. Net income was -$155.2M. SYRE currently screens at market cap $7.60B.
KLAC currently screens at market cap $252.01B and trailing P/E 54.7. SYRE currently screens at market cap $7.60B.
Not investment advice. Open the KLAC and SYRE stock pages for the full models.
Not investment advice.